Abstract
Human immunodeficiency virus infection is an illness with protean manifestations including hematological abnormalities. Thromboembolic complications in HIV-infected patients have been described. Recent literature describes an incidence ranging from 0.26% to 7.6%; higher incidence is seen in patients with active opportunistic infections or malignancy, and in patients with the acquired immunodeficiency syndrome. A variety of potential mechanisms have been proposed to account for the observed hypercoagulability in HIV-infected patients. These include the presence of antiphospholipid- anticardiolipin antibodies, decreased activities of natural anticoagulants (especially protein S), and increased platelet activation. Recent epidemiological studies emphasize the increased incidence of thromboembolic events including myocardial infarction in the HIV-infected population after the introduction of highly active antiretroviral therapy. The use of protease inhibitors in particular is implicated. A hypercoagulable state and especially thromboses are emerging as clinical issues in HIV-infected patients. Further studies are in order to more clearly delineate the pathophysiologic mechanism(s) of thromboses in HIV-infected patients.
Original language | English (US) |
---|---|
Pages (from-to) | 277-280 |
Number of pages | 4 |
Journal | Clinical and Applied Thrombosis/Hemostasis |
Volume | 10 |
Issue number | 3 |
DOIs | |
State | Published - Jul 2004 |
Keywords
- Acquired immunodeficiency syndrome
- Highly active antiretroviral therapy
- Human immunodeficiency virus
- Hypercoagulable state
- Opportunistic infections
- Platelet activation
- Protease inhibitors
- Protein S deficiency
ASJC Scopus subject areas
- Hematology